Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics (Nasdaq: TPST) said it will advance TPST-4003, its CD7-targeted mRNA/LNP in vivo CAR-T using a dual CD19/BCMA CAR, into a first investigator-initiated trial in nervous system autoimmune diseases. The study plans about 10 patients with MG and MS, with first dosing expected in Q4 2026 and initial data in H1 2027.
How this was made
The 30-second read
Why it matters
The announcement provides a concrete clinical timeline and trial design focus (MG and MS), which can shift expectations for development progress and future financing needs, but it does not include new clinical efficacy or safety results.
Market read
A dated, primary clinical milestone (Q4 2026 first dosing) for a next-generation in vivo CAR-T platform can influence trading around development momentum and future catalyst planning.
What to watch
Investors may focus on whether the CD7-tLNP delivery translates into durable CAR expression and manageable immune sensing, which is not yet evidenced by clinical outcomes in this release.
Background
Tempest is developing in vivo CAR-T candidates using CD7-targeted mRNA/LNP delivery, with TPST-4003 built on a dual-targeting CD19/BCMA CAR architecture previously used in TPST-2003.
Ticker impact
Tempest announced TPST-4003 will enter a first investigator-initiated trial in MG and MS, with first patient dosing expected in Q4 2026.
Near-term reaction may be modest unless investors were already positioned for this specific timing; the bigger repricing risk is around future enrollment/first dosing updates and interim safety/pharmacodynamics in 1H/2H 2027.
This is a primary, company-specific clinical development milestone with explicit timing (Q4 2026 dosing) and study size (about 10 patients), but it is investigator-initiated and early-stage, limiting immediate fundamental impact.
Market effects
Reinforces investor interest in in vivo CAR-T delivery platforms (mRNA/LNP) and CD7-targeted approaches for broader T-cell engagement.
Limited direct regional impact; primarily US biotech sentiment.
Modest global read-through for oncology/immunology CAR-T platform competition, without new efficacy data.
Counterpoint
Because the trial is small (about 10 patients) and investigator-initiated, near-term valuation impact may be limited until meaningful safety and pharmacodynamic signals emerge.
Key entities
- CompanyTempest Therapeutics, Inc.
Clinical-stage biotech advancing in vivo CAR-T candidates, including TPST-4003.
- Product candidateTPST-4003
Lead in vivo CAR-T candidate using CD7-targeted mRNA/LNP delivery with dual-targeting CD19/BCMA CAR architecture.
- Program referenceTPST-2003
Earlier clinical-stage CAR-T program whose interim Phase 1/2a data are cited as supporting the CAR construct.
